At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 06-17 16:08:37
9.910
+0.410
+4.32%
High10.040Low9.510Vol1.34M
Open9.540D1 Closing9.500Amplitude5.58%
Mkt Cap10.51BTradable Cap10.51BTotal Shares1.06B
T/O13.17MT/O Rate0.13%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
ASCLETIS-B Executes Share Buyback Totaling HK$1.97 Million
Stock News  ·  06-17 19:26
ASCLETIS-B Executes Share Buyback Totaling HK$1.97 Million
Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellation
Reuters  ·  06-17 19:22
Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellation
ASCLETIS-B Executes Share Buyback, Spending HK$1.86 Million
Stock News  ·  06-16 18:57
ASCLETIS-B Executes Share Buyback, Spending HK$1.86 Million
Ascletis Pharma files HKEX next-day disclosure return reporting share repurchase for cancellation
Reuters  ·  06-16 18:44
Ascletis Pharma files HKEX next-day disclosure return reporting share repurchase for cancellation
ASCLETIS-B Executes Share Buyback, Spending HK$1,918,300 on June 15
Stock News  ·  06-15 17:42
ASCLETIS-B Executes Share Buyback, Spending HK$1,918,300 on June 15
Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellation
Reuters  ·  06-15 17:42
Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellation
One Ascletis Pharma Insider Has Reduced Their Stake
Simply Wall St.  ·  06-13
One Ascletis Pharma Insider Has Reduced Their Stake
Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares
Bulletin Express  ·  06-11
Ascletis Pharma launches fresh HKD 1.97 million buyback; cumulative repurchases reach 7.89 million shares
ASCLETIS-B Executes HK$1.97 Million Share Buyback on June 11
Stock News  ·  06-11
ASCLETIS-B Executes HK$1.97 Million Share Buyback on June 11
Ascletis Pharma Executes HKD 2.00 Million Share Buyback; Cumulative Repurchases Reach 7.69 Million Shares
Bulletin Express  ·  06-10
Ascletis Pharma Executes HKD 2.00 Million Share Buyback; Cumulative Repurchases Reach 7.69 Million Shares
ASCLETIS-B Executes Share Buyback, Spending Nearly HK$2 Million
Stock News  ·  06-10
ASCLETIS-B Executes Share Buyback, Spending Nearly HK$2 Million
Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares
Bulletin Express  ·  06-09
Ascletis Pharma Carries Out HKD 2.01 Million Share Buyback; Cumulative Repurchases Climb to 7.49 Million Shares
Ascletis Pharma repurchases 200,000 shares at HK$9.88–10.26; cumulative buy-backs under mandate rise to 7.29 million
Bulletin Express  ·  06-08
Ascletis Pharma repurchases 200,000 shares at HK$9.88–10.26; cumulative buy-backs under mandate rise to 7.29 million
ASCLETIS-B Executes Share Buyback, Spending HK$2 Million on June 8
Stock News  ·  06-08
ASCLETIS-B Executes Share Buyback, Spending HK$2 Million on June 8
ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation
Stock News  ·  06-08
ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation
Ascletis Highlights Robust Obesity Pipeline with Positive ASC30, ASC37 and ASC39 Results at ADA 2026
Bulletin Express  ·  06-08
Ascletis Highlights Robust Obesity Pipeline with Positive ASC30, ASC37 and ASC39 Results at ADA 2026
Ascletis | Key Resolutions and Timetable for the 2026 Annual General Meeting
Bulletin Express  ·  06-05
Ascletis | Key Resolutions and Timetable for the 2026 Annual General Meeting
Ascletis Pharma to Hold 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and Director Re-elections
Bulletin Express  ·  06-05
Ascletis Pharma to Hold 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and Director Re-elections
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Tiger Newspress  ·  06-05
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
ASCLETIS-B Executes Share Buyback Valued at Approximately HK$2.03 Million
Stock News  ·  06-04
ASCLETIS-B Executes Share Buyback Valued at Approximately HK$2.03 Million
No data available

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--